NCT05973656View on ClinicalTrials.gov

Role of Acetaldehyde in the Development of Oral Cancer

NARecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

September 30, 2027

Conditions
Alcohol-Related CarcinomaFanconi AnemiaOral Cavity Carcinoma
Interventions
DRUG

Alcohol

Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).

PROCEDURE

Biospecimen Collection

Undergo saliva, mouthwash, and cheek brush collection

PROCEDURE

Breath Test

Undergo breathalyzer testing

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT05973656 - Role of Acetaldehyde in the Development of Oral Cancer | Biotech Hunter | Biotech Hunter